Markman on Oncology

• No Benefit to Extending Bevacizumab in Ovarian Cancer   Maurie Markman, MD, discusses results from a pragmatic clinical trial regarding extended frontline treatment with bevacizumab in patients with ovarian cancer.
  Medscape Oncology, October 16, 2023
• Long-Term Results Show Major Advance in Endometrial Cancer   Maurie Markman, MD, discusses a long-term follow-up trial demonstrating response in patients with endometrial cancer.
  Medscape Oncology, October 04, 2023
• Opportunities for Cancer Prevention Over the Next 30 Years   Maurie Markman, MD, discusses global estimates for the economic costs of cancer over the next 30 years, emphasizing the opportunity for cancer prevention.
  Medscape Oncology, October 03, 2023
• Two Landmark Papers Change Paradigm for Endometrial Cancer   Maurie Markman, MD, discusses landmark studies that change the management paradigm for advanced endometrial cancer.
  Medscape Oncology, September 18, 2023
• Women ≥ 65 Years: When to Screen for Cervical Cancer   Maurie Markman, MD, discusses a recent paper demonstrating that older women are diagnosed with more advanced cervical cancer.
  Medscape Oncology, July 17, 2023
• Brisk Walking: No-Cost Option to Improve Cancer Outcomes   Maurie Markman, MD, discusses a recent paper describing the benefits of walking in patients with stage III colon cancer.
  Medscape Oncology, July 12, 2023
• Immunotherapy Toxicity: How Much Do Physicians Know?   Maurie Markman, MD, discusses physician awareness of immune-related adverse events associated with immune checkpoint inhibitors.
  Medscape Oncology, March 15, 2023
• Cancer Statistics: Public Health Improvements and Future Thoughts   Maurie Markman, MD, discusses the most recent paper describing cancer statistics.
  Medscape Oncology, March 07, 2023
• Advanced Ovarian Cancer: 20% Disease-Free Survival at 10 Years   Maurie Markman, MD, discusses a recent paper on the 10-year survival rate of patients with stage III ovarian cancer.
  Medscape Oncology, February 07, 2023
• Is Trametinib a New Standard for Low-Grade Serous Ovarian Cancer?   Is it possible that a new standard of care is emerging in low-grade serous ovarian cancer? Dr Maurie Markman discusses a study that shows clear benefit with trametinib.
  Medscape Oncology, January 25, 2023
• Behavioral Modification Could Prevent Nearly 50% of Cancer Deaths   Maurie Markman, MD, discusses findings from a recent article demonstrating that nearly half of all cancer deaths could be prevented with behavioral modification.
  Medscape Oncology, December 14, 2022
• Bariatric Surgery Reduces Obesity-Related Cancer Risk   Maurie Markman, MD, discusses results from a case-control study of individuals with high BMI, demonstrating reduced obesity-related cancer risk following bariatric surgery.
  Medscape Oncology, December 12, 2022
• SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib   Maurie Markman, MD, discusses 7-year follow-up results of the SOLO1 study in patients with advanced ovarian cancer and a BRCA mutation.
  Medscape Oncology, December 12, 2022
• Reassuring Data: Olaparib Dose Reductions Have Minimal Effect   Dr Maurie Markman discusses a recent paper describing olaparib interruptions and dose reductions in ovarian cancer.
  Medscape Oncology, September 14, 2022
• Ovarian Cancer Is Not Silent: Common, Nonspecific Symptoms   Dr Maurie Markman discusses a recent publication on the symptoms of early-stage, high-risk ovarian cancer.
  Medscape Oncology, September 13, 2022
• Synergy With Combo Checkpoint Inhibitors: Fact or Fiction?   Dr Maurie Markman highlights a new paper questioning whether there is synergy among checkpoint inhibitors used in combination.
  Medscape Oncology, July 27, 2022
• Single-Dose HPV Vaccination Strategy May Be Coming   Are we being single-minded about cervical cancer prevention? Hear Dr Maurie Markman discuss a pivotal paper that says one dose of an HPV vaccine may be enough.
  Medscape Oncology, July 26, 2022
• Gynecologic Cancer Studies: What to Look for at ASCO 2022   It's not just about ovarian cancer anymore -- presentations at ASCO 2022 illustrate the major advances that have been made in gynecologic cancer treatments.
  Medscape Oncology, May 20, 2022
• Young Adult Obesity Has Quintupled. Will 'Cancer Wave' Follow?   Maurie Markman discusses a recent article highlighting obesity prevalence among young adults with an eye toward the implications for cancer incidence in the United States.
  Medscape Oncology, May 09, 2022
• Cancer Data Reproducibility Problem Undermines Public Trust   Dr Maurie Markman discusses problems with the replicability of research published in high-impact medical journals and the potential implications.
  Medscape Oncology, April 27, 2022